Number	Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for Delay	Comments	Reasons for delay correspond to:
1	155747	16/YH/0459	213518	OPTION-DM	No		21			09/11/2016	08/01/2019	25/07/2017	22/11/2018	29/01/2019	Please Select...	27/02/2019	D - Sponsor Delays	Delayed sponsor green light. Participants sought but no eligible participants identified.	Sponsor
2	155748	17/SC/0070	215616	RCT Prepare for Kidney Care	Yes	02/07/2019	1	131	132	23/11/2018	20/02/2019	23/03/2018	08/02/2019	21/02/2019	Please Select...	25/02/2019	F - No patients seen	Participants sought but no eligible participants identified until 02/07/2019.	Neither
3	155749	18/SC/0243	240684	ORION-4	Yes	15/10/2019	14	54	68	30/01/2018	08/08/2019	17/10/2018	07/08/2019	22/08/2019	Please Select...	23/09/2019			Please Select...
4	155750	17/LO/1847	216867	MUK Twelve	Yes	25/07/2019	0	76	76	17/05/2018	10/05/2019	04/01/2018	21/03/2019	10/05/2019	Please Select...	06/06/2019	D - Sponsor Delays	Delayed sponsor green light.	Sponsor
5	155751	16/EE/0065	192416	Cholecalciferol in Patients on Dialysis - SIMPLIFIED	Yes	04/07/2019	7	105	112	14/06/2018	14/03/2019	29/07/2016	12/03/2019	21/03/2019	Please Select...	13/06/2019	D - Sponsor Delays	Delayed sponsor green light.	Sponsor
6	155752	16/NW/0629	211995	CF START	No		7			26/06/2018	21/02/2019	22/09/2016	07/02/2019	28/02/2019	Please Select...	04/04/2019	D - Sponsor Delays	Delayed sponsor green light, as sponsor was moving office and required to organise the move, greenlight was therefore delayed. Site was therefore unable to recruit participant waiting to enter the study.	Sponsor
7	155753	18/NW/0514	249725	EX9536-4388 SELECT semaglutide cardiovascular outcome trial	Yes	20/03/2019	0	40	40	16/04/2018	08/02/2019	01/02/2019	06/02/2019	08/02/2019	Please Select...	01/03/2019			Please Select...
8	155754	18/EE/0373	249396	Breast Cancer Her 2	No		13			21/08/2018	20/09/2019	11/01/2019	19/09/2019	03/10/2019	Please Select...		D - Sponsor Delays	Awaiting sponsor greenlight.	Sponsor
9	155755	19/EM/0240	253425	TARGET Pilot, FOCUS & TARGET	Yes	07/10/2019	3	24	27	04/08/2017	10/09/2019	06/09/2019	13/09/2019	13/09/2019	Please Select...	13/09/2019			Please Select...
10	155756	17/SS/0082	222441	SoSTART	Yes	31/05/2019	0	85	85	20/06/2018	07/03/2019	05/10/2017	14/01/2019	07/03/2019	Please Select...	09/04/2019	D - Sponsor Delays	Delay in receiving sponsor green light due to exchange of documents between sponsor and site.	Both
11	155801	18/EE/0236	242210	FDC products in PDN	No		13			14/06/2018	04/04/2019	19/10/2018	27/03/2019	17/04/2019	Please Select...	21/06/2019	D - Sponsor Delays F - No patients seen	Delayed sponsor green light. Participants sought but no eligible participants identified.	Sponsor
12	155802	17/NE/0176	219406	JEWELFISH	Yes	24/09/2019	5	21	26	02/08/2018	29/08/2019	05/09/2017	02/09/2019	03/09/2019	Please Select...	09/09/2019			Please Select...
13	155803	18/EM/0229	250101	PROTECT 021IGAN17001	Yes	03/07/2019	7	118	125	02/03/2018	28/02/2019	04/10/2018	27/02/2019	07/03/2019	Please Select...	14/05/2019	D - Sponsor Delays F - No patients seen	Delayed sponsor green light. Participants sought but no eligible participants identified until 03/07/2019.	Sponsor
14	155804	18/NE/0072	235113	CITADEL-205	Yes	19/08/2019	0	115	115	03/08/2018	26/04/2019	18/05/2018	18/04/2019	26/04/2019	Please Select...	29/05/2019	D - Sponsor Delays	Protocol amendment received just before site due to open. The amendment directly affected pharmacy, therefore local pharmaceutical review required time.	Sponsor
15	155805	18/NW/0098	242717	Repeat doses of BAY 1902607 in healthy males and proof of concept in	Yes	18/03/2019	10	25	35	07/09/2018	11/02/2019	14/05/2018	07/02/2019	21/02/2019	Please Select...	26/02/2019			Please Select...
16	155806	19/LO/0050	253551	M14-239 Open Label Teliso-V in c-Met Postive NSCLC Patients	No		22			13/09/2018	26/09/2019	19/02/2019	20/09/2019	18/10/2019	Please Select...	04/11/2019	F - No patients seen	Participants sought but no eligible participants identified. It is exceptionally rare to come by patients who are c-met positive.	Neither
17	155807	18/YH/0393	253270	BP40657 - Atezolizumab SC in patients with NSCLC	Yes	13/06/2019	8	98	106	23/07/2018	27/02/2019	19/12/2018	06/03/2019	07/03/2019	Please Select...	11/06/2019	D - Sponsor Delays	Delayed sponsor green light.	Sponsor
18	155808	18/YH/0392	252761	GB001 in adult subjects with moderate to severe asthma	Yes	10/09/2019	1	173	174	21/09/2018	20/03/2019	15/11/2018	12/03/2019	21/03/2019	Please Select...	29/03/2019	D - Sponsor Delays	Sponsor failed to provide training and send necessary equipment to begin the trial.	Sponsor
19	155809	19/NW/0026	249432	VX18-121-101 Safety and Efficacy of VX-121 combination therapy in CF	Yes	19/06/2019	6	14	20	20/09/2018	30/05/2019	12/03/2019	29/05/2019	05/06/2019	Please Select...	06/06/2019			Please Select...
20	155810	18/YH/0476	255167	PACIFIC-4/RTOG-3515: SBRT with Durvalumab/Placebo in Stage I/II NSCLC	Yes	22/08/2019	27	29	56	19/10/2018	27/06/2019	25/03/2019	19/06/2019	24/07/2019	Please Select...	25/07/2019			Please Select...
21	155811	18/LO/1810	252582	Randomised feasibility trial of an onward HIV disclosure intervention	Yes	18/09/2019	1	21	22	30/09/2018	27/08/2019	10/01/2019	28/08/2019	28/08/2019	Please Select...	28/08/2019			Please Select...
22	155812	18/EM/0310	239782	C-STICH2 Randomised controlled trial of emergency cerclage	No		7			24/10/2018	21/02/2019	16/01/2019	06/02/2019	28/02/2019	Please Select...	05/03/2019	F - No patients seen	Participants sought but no eligible participants identified.	Neither
23	155813	19/SC/0034	254823	GLPG1690-CL-303	No		34			05/07/2018	26/06/2019	29/04/2019	18/07/2019	30/07/2019	Please Select...	29/08/2019	D - Sponsor Delays F - No patients seen	Greenlight was delayed until training SIV took place. Participants sought but no participants identified.	Sponsor
24	155814	18/YH/0477	253254	A Phase 3 study of Zanubrutinib compared with Ibrutinib	Yes	07/08/2019	15	68	83	22/11/2018	16/05/2019	23/01/2019	28/05/2019	31/05/2019	Please Select...	02/07/2019	D - Sponsor Delays E - Staff availability issues	Delayed sponsor greenlight	Sponsor
25	155815	19/NW/0161	257243	Phase 2 study to evaluate PUR1900 in asthmatic patients with ABPA	No		10			31/10/2018	30/07/2019	15/04/2019	24/07/2019	09/08/2019	Please Select...	15/08/2019	F - No patients seen	Participants sought but no eligible participants identified. It is rare to come by patients with ABPA and no other health problems.	Neither
26	155816	18/LO/2146	255809	INC280 + PDR001 versus docetaxel in pre-treated, advanced ALK-ve NSCLC	No		2			05/12/2018	14/05/2019	23/01/2019	30/04/2019	16/05/2019	Please Select...		D - Sponsor Delays	Awaiting sponsor greenlight.	Sponsor
27	155817	17/NE/0325	227986	EMPOWER Trial	No		27			03/12/2018	15/03/2019	30/11/2017	27/03/2019	11/04/2019	Please Select...		J - Other	Withdrawn from the study. Change in Clinical Services.	NHS Provider
28	155818	19/LO/0553	257627	GALACTIC-1 Phase 2b study in idiopathic pulmonary fibrosis (IPF)	No		0			30/11/2018	20/11/2019	24/09/2019	13/11/2019	20/11/2019	Please Select...	27/11/2019			Please Select...
29	155819	18/SS/0125	237740	PIBCAP	No		26			22/11/2018	19/09/2019	14/12/2018	27/09/2019	15/10/2019	Please Select...		D - Sponsor Delays	Awaiting sponsor greenlight.	Sponsor
30	155820	19/YH/0093	255567	ATLAS Study	No					03/01/2019	10/12/2019	04/06/2019			Please Select...				Please Select...
31	155821	18/SS/0085	243640	Alpha-2 agonists for sedation (A2B Trial)	Yes	04/10/2019	1	15	16	14/12/2018	18/09/2019	16/01/2019	04/09/2019	19/09/2019	Please Select...	03/10/2019			Please Select...
32	155822	18/NE/0235	244048	VISION DMD	Yes	12/11/2019	8	40	48	17/01/2019	25/09/2019	21/09/2018	12/09/2019	03/10/2019	Please Select...	09/10/2019			Please Select...
33	155823	19/SW/0041	260477	Pembrolizumab + Lenvatinib verses Docetaxel in 2L+ NSCLC (LEAP-008)	No		0			02/10/2018	06/11/2019	02/04/2019	01/10/2019	06/11/2019	Please Select...	13/11/2019			Please Select...
34	155824	19/EM/0051	257138	CTP-102	Yes	05/09/2019	3	90	93	20/12/2018	04/06/2019	28/03/2019	03/06/2019	07/06/2019	Please Select...	21/08/2019	A - Permissions delayed/denied	Pharmacy review and approval was delayed	NHS Provider
35	155825	19/YH/0049	258945	A Phase 1c Study of Single Dose MTPS9579A in Patients with Asthma	No		4			05/03/2019	11/10/2019	04/06/2019	04/09/2019	15/10/2019	Please Select...	05/11/2019	G - No patients consented	Participants are required to have two bronchoscopys which has caused some reluctance to participate.	Neither
36	155826	19/WM/0039	257987	FLOW (NN9535-4321) Semaglutide renal outcomes trial	Yes	07/08/2019	3	54	57	05/11/2018	11/06/2019	15/04/2019	13/06/2019	14/06/2019	Please Select...	09/07/2019			Please Select...
37	155827	17/LO/0962	220190	Pregnancy Trial of E-cigarettes and Patches (PREP)	Yes	31/05/2019	7	15	22	07/01/2019	09/05/2019	24/07/2017	23/04/2019	16/05/2019	Please Select...	28/05/2019			Please Select...
38	155828	19/WM/0097	246910	Project MURRAY: Feasibility Study	No					27/02/2019	19/12/2019	11/07/2019			Please Select...				Please Select...
39	155829	18/SC/0624	244229	Short or Long Antibiotic Regimes in Orthopaedics (SOLARIO)	Yes	24/10/2019	3	98	101	24/12/2018	15/07/2019	21/12/2019	18/07/2019	18/07/2019	Please Select...	19/07/2019	F - No patients seen	Participants sought but no eligible participants identified.	Neither
40	155830	19/WM/0164	261698	iSTABILISE	Yes	13/06/2019	5	1	6	04/10/2018	07/06/2019	06/06/2019	12/06/2019	12/06/2019	Please Select...	12/06/2019			Please Select...
41	155831	19/EM/0189	264788	Pembrolizumab with or without olaparib in metastatic squamous NSCLC	No		2			10/03/2019	06/11/2019	14/08/2019	15/10/2019	08/11/2019	Please Select...	06/12/2019			Please Select...
42	155832	18/LO/2045	252053	The Radiance II Pivotal study in Stage II Hypertension.	No		5			24/04/2019	12/12/2019	25/01/2019	04/12/2019	17/12/2019	Please Select...				Please Select...
43	155833	19/EM/0220	265213	Switching to DTG/3TC in virologically suppressed HIV-infected adults	No		1			01/03/2019	12/11/2019	11/09/2019	31/10/2019	13/11/2019	Please Select...				Please Select...
44	155834	19/NW/0482	269475	Kepler	Yes	08/11/2019	1	17	18	30/05/2019	21/10/2019	27/09/2019	15/10/2019	22/10/2019	Please Select...	30/10/2019			Please Select...
45	155835	18/NS/0145	254786	IMreal	No		7			05/07/2019	09/10/2019	07/02/2019	14/10/2019	16/10/2019	Please Select...	17/10/2019	F - No patients seen	Strict participant eligibility criteria, no new patients on the drug required for the study. In some instances participants have been identified but have not been able to consent to the study as they are too unwell, e.g. now in hospice care.	Neither
46	155850	19/YH/0229	266822	Efficacy and Safety of Benralizumab in Moderate to Very Severe COPD	No		1			21/08/2019	11/12/2019	07/09/2019	09/12/2019	12/12/2019	Please Select...	18/12/2019			Please Select...
47	155851	17/LO/1245	208149	Metronidazole Versus lactic acId for Treating bacterial vAginosis–VITA	Yes	19/03/2019	8	47	55	16/08/2018	23/01/2019	10/11/2017	31/01/2019	31/01/2019	Please Select...	21/02/2019			Please Select...
48	155852	17/NW/0529	226070	PPAC2: Packing of Perianal Abscess Cavities 2	Yes	27/03/2019	21	34	55	22/05/2018	31/01/2019	05/12/2017	07/02/2019	21/02/2019	Please Select...	12/03/2019			Please Select...
49	155853	17/YH/0228	222492	CALM-2	No		4			16/05/2018	04/01/2019	05/10/2017	02/01/2019	08/01/2019	Please Select...	08/01/2019	F - No patients seen	Participants sought but no eligible participants identified.	Neither
50	155854	18/EM/0112	236871	ALL-RIC	No					11/12/2018	27/11/2019	12/06/2018	12/12/2019		Please Select...				Please Select...
51	155875	18/NE/0006	227090	Repair of ARDS by Stromal Cell Administration (REALIST)	No		11			16/05/2017	21/02/2019	06/08/2018	15/02/2019	04/03/2019	Please Select...	24/04/2019	D - Sponsor Delays	Only one patient per site can be active at any one time. Recruitment is also now paused as the sponsor is investigating IMP.	Sponsor
52	155876	18/YH/0322	226765	SUNRRISE	Yes	24/04/2019	8	14	22	06/03/2018	02/04/2019	26/10/2018	01/04/2019	10/04/2019	Please Select...	10/04/2019			Please Select...
53	155877	19/WA/0019	247285	Reduction Of Surgical Site Infection using several Novel Interventions	Yes	21/05/2019	0	8	8	30/10/2018	13/05/2019	01/02/2019	13/05/2019	13/05/2019	Please Select...	17/05/2019			Please Select...
54	155878	18/NE/0296	248487	CALIBRE Study	Yes	25/03/2019	6	26	32	19/10/2018	21/02/2019	19/10/2018	08/02/2019	27/02/2019	Please Select...	05/03/2019			Please Select...
55	155879	19/YH/0054	258802	SWHSI 2	Yes	27/11/2019	9	33	42	27/02/2019	16/10/2019	05/04/2019	15/10/2019	25/10/2019	Please Select...	12/11/2019			Please Select...
56	155880	18/SS/0033	242190	BICS Cardiac sub-study	No		1			19/08/2019	19/08/2019	09/08/2018	19/08/2019	20/08/2019	Please Select...	16/09/2019	G - No patients consented	Only 1 eligible participant seen since study opening, participant did not consent to take part in the study.	Neither
57	155908	18/EM/0190	243165	A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome	Yes	01/05/2019	0	118	118		03/01/2019	14/09/2018	19/12/2018	03/01/2019	Please Select...	03/01/2019	E - Staff availability issues	Initially staff availability issues delayed commencement. Since opening we have screened 19 patients.	NHS Provider

58	155909	18/SC/0368	242984	A Phase II pilot safety and tolerability study of ILB in patients with Motor Neurone Disease (MND)/ Amyotrophic Lateral Sclerosis (ALS)	Yes	28/03/2019			79		08/01/2019	09/08/2018			Please Select...	08/01/2019	D - Sponsor Delays	There were delays with the Sponsor providing the correct paperwork. Due to Sponsor error the IMP was not delivered until 2 months post. We consented our first patient 9 days later on 21st March.	Sponsor
59	155910	18/YH/0398	251963	FreeStyle Libre Flash Glucose Monitoring System use in Insulin Treated Patients Undergoing Dialysis	Yes	17/01/2019			7		10/01/2019	17/10/2018			Please Select...	09/01/2019			Please Select...
60	155911	18/LO/0727	245123	Post-Market Clinical Follow-Up Study to Monitor Device Performance and Outcomes of the CENTERA Transcatheter Heart Valve System	Yes	08/05/2019	0	111	111		17/01/2019	22/08/2018	30/11/2018	17/01/2019	Please Select...	17/01/2019	D - Sponsor Delays	We were all set up and had an SIV booked for November 13th 2018 and then the 6th February 2019 but the SIVs were postponed both times by the sponsor. The SIV has now been booked for the 29th April.	Sponsor
61	155912	18/LO/0855	237285	A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 versus Sorafenib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma	Yes	20/03/2019	0	58	58	30/08/2018	21/01/2019	31/08/2018	18/01/2019	21/01/2019	Please Select...	21/01/2019			Please Select...
62	155913	18/WM/0039	236159	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Completed the Studies M14-431 or M14-433	No		0				01/02/2019	26/03/2018	29/01/2019	01/02/2019	Please Select...	01/02/2019	F - No patients seen	We can't recruit into RRK6268 - M14-430 until we have recruited into both RRK6270 - M14-433 and RRK6269 M14 431.	Neither
63	155914	18/WM/0037	228917	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or are Intolerant to Biologic Therapy	No		0				01/02/2019	26/03/2018	28/01/2019	01/02/2019	Please Select...	01/02/2019	G - No patients consented	At present there is another high priority competing study and all eligible patients are being put onto this study first.	NHS Provider
64	155915	18/WM/0038	235048	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or are Intolerant to Conventional Therapies but Have Not Failed Biologic Therapy	No		0				01/02/2019	26/03/2018	28/01/2019	01/02/2019	Please Select...	01/02/2019	G - No patients consented	At present there is another high priority competing study and all eligible patients are being put onto this study first.	NHS Provider
65	155916	18/EM/0281	251974	Long-term extension trial in subjects with atopic dermatitis who participated in previous tralokinumab trials ? ECZTEND	Yes	12/02/2019	0	7	7		05/02/2019	14/11/2018	01/02/2019	05/02/2019	Please Select...	05/02/2019			Please Select...
66	155917	17/YH/0391	229417	Double-blind, randomized, placebo-controlled, phase III study comparing norursodeoxycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis	Yes	11/06/2019	0	119	119	05/11/2018	12/02/2019	12/02/2018	08/02/2019	12/02/2019	Please Select...	12/02/2019	G - No patients consented		Neither
67	155920	17/WS/0147	184216	Precision-Panc Master Protocol Personalising Treatment For Pancreatic Cancer	No		3			30/08/2018	18/02/2019	05/01/2018	19/02/2019	21/02/2019	Please Select...	06/02/2019	D - Sponsor Delays	Recruitment to this study requires the Primus-001 study to be open/recruiting, which has been delayed in opening due to substantial amendments being made and Sponsor delays in submitting documents for approval.	Sponsor
68	155921	18/EM/0320	251945	A Phase Ib/IIa, Randomised, Double Blind, Placebo-Controlled Trial to Investigate the Safety, Tolerability and Clinical Activity of Humanised Antibody GSK1070806 in the Treatment of Patients with Moderate-to-Severe Crohn's Disease	Yes	13/05/2019			82		20/02/2019	19/12/2018			Please Select...	11/02/2019	G - No patients consented	Eligible patient's preferred SOC treatment. We recruited our first patient on day 82.	Neither
69	155922	18/YH/0063	234608	A Prospective, Multi-Center Evaluation of the ENSEAL X1 Large Jaw Tissue Sealer	Yes	21/03/2019			27	14/11/2018	22/02/2019	18/07/2018			Please Select...	22/02/2019			Please Select...
70	155923	18/NI/0195	251134	SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects with Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype	Yes	20/05/2019	0	80	80		01/03/2019	17/12/2018	18/02/2019	01/03/2019	Please Select...	01/03/2019	G - No patients consented	We have so far Screened 5 patients. Unfortunately CT showed disease progression for the first 2 patients making them ineligible and the third patient was found not to be eligible. We have so far recruited 2 patients, our first on 20th May (80 days).	Neither
71	155926	18/WA/0154	233884	A Randomised Controlled Trial of low dose single antibiotic loaded cement versus high dose dual antibiotic loaded cement in patients receiving a hip hemiarthroplasty after fracture	Yes	09/05/2019	3	63	66		04/03/2019	10/05/2018	04/03/2019	07/03/2019	Please Select...	20/02/2019			Please Select...
72	155927	18/WM/0102	217834	A prospective, phase II, single centre, cross-sectional, randomised study investigating Dehydroepiandrosterone and Pharmacokinetics in Trauma	Yes	01/04/2019			27		05/03/2019	11/06/2018			Please Select...	27/02/2019			Please Select...
73	155928	18/LO/1706	252196	A Phase 2, proof-of-concept, multicentre, double-blind, randomised, doseascending, sequential group, placebo-controlled study to evaluate the mechanistic effect, safety, and tolerability of 12 weeks twice daily oral administration of alvelestat (MPH966) in participants with alpha-1 (PiZZ or null genotype/phenotype) antitrypsin deficiency.	Yes	17/04/2019			36		12/03/2019	30/11/2018			Please Select...	12/03/2019			Please Select...
74	155929	18/YH/0324	217826	A Clinical Trial to investigate biomarker effects of pre-surgical treatment with DDR agents in patients with Head and Neck Squamous Cell Carcinoma (HNSCC) who are planned to undergo surgery that is likely to be followed by radiotherapy and/or chemotherapy	No		0			30/08/2018	21/03/2019	13/12/2018	20/03/2019	21/03/2019	Please Select...	21/03/2019	G - No patients consented	Eligible patients must be consented post diagnosis but prior to surgery. Patients are not inclined to take part in a clinical trial with unknown benefit before surgery.	Neither
75	155930	18/EM/0384	252990	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VT-1161 Oral Capsules in the Treatment of Subjects with Recurrent Vulvovaginal Candidiasis	Yes	09/05/2019	0	48	48		22/03/2019	08/01/2019	21/03/2019	22/03/2019	Please Select...	20/03/2019			Please Select...
76	155931	18/LO/0569	233097	A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTICENTER CLINICAL TRIAL ON HOME PARENTERAL NUTRITION USING AN OMEGA-3 FATTY ACID ENRICHED MCT/LCT LIPID EMULSION	Yes	04/12/2019	1	253	254		25/03/2019	04/06/2018	14/02/2019	26/03/2019	Please Select...	22/03/2019	D - Sponsor Delays	After R&D approval the sponsor asked for more technical information from the laboratories regarding a specific blood test. We are currently discussing what technical information labs can provide to confirm that we can reliably measure the sample (conjugated bilirubin).	Sponsor
77	155933	17/SC/0476	186573	Macular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy (MERIT) Trial	Yes	23/05/2019			59	10/07/2018	25/03/2019	07/11/2017			Please Select...	22/03/2019			Please Select...
78	155934	18/EM/0147	238388	ATLAS: A Phase 2, Open-label Study of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma	No		0			05/10/2018	28/03/2019	26/09/2018	14/03/2019	28/03/2019	Please Select...	27/03/2019	C - Closed by sponsor	Closed 19/04 by Sponsor at all sites as the drug was found to be unbeneficial to the patient.	Sponsor
79	155935	18/SC/0155	236211	A multicentre international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess cardio-renal outcomes in patients with chronic KIDNEY disease	Yes	09/09/2019	2	158	160		02/04/2019	26/04/2019	02/04/2019	04/04/2019	Please Select...	02/04/2019	D - Sponsor Delays	We had 4 patients within the 70 day target that had agreed to take part in the trial, however the Sponsor does not want us to consent any subjects to the study until we have screened 50 patients. We can then start the consent process to get the target of 32 patients randomised to the study.	Sponsor
80	155936	18/LO/2109	253115	EXerCise Intervention in cholesTatic LivEr Disease: The EXCITED study	Yes	08/04/2019	60	-57	3		05/04/2019	02/01/2019		04/06/2019	Please Select...	05/04/2019			Please Select...
81	155938	18/NW/0215	239446	A Phase 2, Randomized, Placebo-Controlled Study of Safety and Efficacy, Following Repeat-Dose Administration of Evinacumab (anti-ANGPTL3) in Patients with Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis	Yes	23/05/2019	0	45	45		08/04/2019	20/07/2018	03/04/2019	08/04/2019	Please Select...	08/04/2019			Please Select...
82	155939	19/SC/0027	250129	A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers	Yes	02/11/2019	0	200	200	02/07/2018	16/04/2019	07/03/2019	08/04/2019	16/04/2019	Please Select...	09/04/2019	B - Suspended by sponsor	The Sponsor paused enrolment after 16 days as they had sufficient participants in screening to fill the remaining available slots for part 1 of the trial.	Sponsor
83	155940	17/LO/0621	191390	STandard versus Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI): A Multi-Centre Randomized Controlled Trial	No					17/08/2018	29/04/2019	22/05/2017			Please Select...	12/04/2019	D - Sponsor Delays	Delayed Sponsor Green Light- Sponsor delayed confirmation of study open to recruitment at site	Sponsor
84	155941	18/YH/0014	224065	External frame versus internal locking plate for articular pilon fracture fixation in adult patients - a multi-centre randomised controlled trial	Yes	01/08/2019	7	86	93		30/04/2019	13/02/2018		07/05/2019	Please Select...	25/04/2019	D - Sponsor Delays	Delayed Sponsor Green Light- sponsor delayed confirmation of study open to recruitment at site	Sponsor

85	155942	18/NW/0813	256738	A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patients with moderate to severe hidradenitis suppurativa (SUNRISE)	Yes	25/06/2019			54	11/05/2018	02/05/2019	16/01/2019			Please Select...	02/05/2019			Please Select...
86	155943	16/EM/0344	180454	The effect of MultiPoint? pacing on reverse remodelling and the incidence of ventricular arrhythmias ? The MPP VARR Study	No						07/05/2019	26/10/2016			Please Select...	07/05/2019	E - Staff availability issues	Staff availability at site	NHS Provider
87	155944	17/WS/0142	221370	PRIMUS 001: A PRECISION PANC CLINICAL STUDY An adaptive phase II study of FOLFOX-A (FOLFOX and nab-paclitaxel) versus AG (nab-paclitaxel and gemcitabine) in patients with metastatic pancreatic cancer, with integrated biomarker evaluation	No		3			10/10/2017	17/05/2019	07/09/2017		20/05/2019	Please Select...	13/03/2019	D - Sponsor Delays	Delayed Sponsor Green Light-sponsor delayed confirmation of study open to recruitment at site	Sponsor
88	155945	19/NE/0007	252984	A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults with Generalized Myasthenia Gravis	Yes	11/11/2019	0	174	174		21/05/2019	05/02/2019	08/05/2019	21/05/2019	Please Select...	21/05/2019	D - Sponsor Delays	Sponsor wanted a separate SIV for pharmacy but then gave Green Light and forgot to arrange pharmacy SIV. A lack of response from the sponsor to arrange this caused further delays. Sponsor also failed to provide manufacturing information to medical engineering causing more delays.	Sponsor
89	155946	19/LO/0355	251449	Evaluation of the benefits of bilateral fitting in bone-anchored hearing system users	Yes	04/07/2019			44		21/05/2019	13/03/2019	16/05/2019		Please Select...	20/05/2019			Please Select...
90	155947	18/LO/0779	235161	A RANDOMIZED (1:1), DOUBLE-BLIND, MULTI-CENTER, PLACEBO CONTROLLED STUDY EVALUATING INTENSIVE CHEMOTHERAPY WITH OR WITHOUT GLASDEGIB (PF-04449913) OR AZACITIDINE (AZA) WITH OR WITHOUT GLASDEGIB IN PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA	Yes	05/07/2019	0	37	37	12/10/2017	29/05/2019	15/06/2018	21/05/2019	29/05/2019	Please Select...	29/05/2019			Please Select...
91	155948	18/WS/0201	251717	A 52-week, placebo-controlled, randomized, Phase 3 study to evaluate the safety and efficacy of seladelpar in subjects with primary biliary cholangitis (PBC) and an inadequate response to or an intolerance to ursodeoxycholic acid (UDCA)	No		0				06/06/2019	21/02/2019	29/05/2019	06/06/2019	Please Select...	05/06/2019	G - No patients consented	We have pre-screened 18 patients, 3 are considering, 3 declined and the rest failed inclusion/exclusion criteria	Neither
92	155949	18/EM/0280	245964	A FIRST IN HUMAN MULTI-CENTER, OPEN LABEL, PROSPECTIVE STUDY TO EVALUATE THE SAFETY, USABILITY AND PERFORMANCE OF THE V-LAP SYSTEM	Yes	11/07/2019	0	30	30		11/06/2019	27/01/2019	02/06/2019	11/06/2019	Please Select...	10/06/2019			Please Select...
93	155950	19/EM/0063	253607	"A Double-Blind, Phase III, Randomised Study to Compare the Efficacy and Safety of Oral Azacitidine (CC-486) Versus Placebo in Subjects with Acute Myeloid Leukaemia or Myelodysplastic Syndromes as Maintenance after Allogeneic Haematopoietic Stem Cell Transplantation (AMADEUS)"	Yes	17/06/2019	0	6	6	01/02/2019	11/06/2019	14/05/2019	07/06/2019	11/06/2019	Please Select...	31/05/2019			Please Select...
94	155951	18/LO/0996	244434	Characterization of Acute and Long Term Response to Left Ventricle Only Pacing Combined with MultiPoint Pacing and SyncAV	No		1				17/06/2019	07/09/2018	16/05/2019	18/06/2019	Please Select...	17/06/2019	D - Sponsor Delays	Sponsor had to re-apply for ethics and HRA approval after amending PIS	Sponsor
95	155952	17/NE/0339	214254	A 2x2 factorial randomised examiner blind open label trial to determine the Clinical and cost- Effectiveness of hypertonic saline (HTS 6%) and carbocisteine for Airway cleaRance versus usual care over 52 weeks in bronchiectasis	Yes	18/11/2019			146		25/06/2019	23/04/2018			Please Select...	25/06/2019	E - Staff availability issues	Staff availability for training due to annual leave	NHS Provider
96	155953	16/EM/0322	202096	Tenecteplase in Wake-up Ischaemic Stroke Trial (TWIST)	Yes	11/11/2019			139	02/10/2018	25/06/2019	18/08/2017			Please Select...	24/06/2019	H - Contracting delays	Contracting delays- Sponsor delayed signing the contract after R&D approval	Sponsor
97	155954	18/LO/1187	240011	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy	No		0			08/08/2018	26/06/2019	11/09/2018	21/06/2019	26/06/2019	Please Select...	26/06/2019	E - Staff availability issues	Staff availability issues at site	NHS Provider
98	155955	19/SC/0023	255292	An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection (subcutaneous use) in Patients with Primary Hyperoxaluria	Yes	09/07/2019	0	13	13		26/06/2019	01/03/2019	21/06/2019	26/06/2019	Please Select...	26/06/2019			Please Select...
99	155956	19/EE/0124	260061	Investigation of efficacy and safety of semaglutide s.c. once-weekly versus placebo in subjects with non-alcoholic steatohepatitis and compensated liver cirrhosis	Yes	13/08/2019	0	48	48		26/06/2019	13/05/2019	24/06/2019	26/06/2019	Please Select...	26/06/2019			Please Select...
100	155957	19/SC/0035	259136	A Phase 2 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of DCR-PHXC Solution for Injection (subcutaneous use) in Patients with Primary Hyperoxaluria	No		0			10/07/2018	26/06/2019	10/04/2019	25/06/2019	26/06/2019	Please Select...	26/06/2019	D - Sponsor Delays	Delayed Sponsor Green Light-sponsor delayed confirmation of study open to recruitment at site	Sponsor
101	155966	19/LO/0344	257615	AN OBSERVER-BLIND, RANDOMIZED STUDY WITH AN OPEN-LABEL PART TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SUBCUTANEOUS ADMINISTRATION OF RO7191863 WITH MULTIPLE DOSES AND DIFFERENT REGIMENS IN VIROLOGICALLY SUPPRESSED PATIENTS WITH CHRONIC HEPATITIS B INFECTION	No		5				18/07/2019	25/04/2019	12/07/2019	23/07/2019	Please Select...	18/07/2019	D - Sponsor Delays	Delayed Sponsor Green Light - sponsor delayed confirmation of study open to recruitment at site	Sponsor
102	155967	19/SC/0021	249552	OPtimal TIMing of Anticoagulation after acute ischaemic Stroke: a randomised controlled trial (OPTIMAS Trial)	Yes	31/10/2019			105	03/04/2019	18/07/2019	04/04/2019	26/07/2019		Please Select...	17/07/2019	H - Contracting delays	Funding issue regarding imaging which has now been resolved.	Both
103	155968	19/EM/0062	256447	A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of ST-0529 in Subjects with Moderately to Severely Active Ulcerative Colitis.	No		1			07/01/2019	23/07/2019	12/04/2019	22/07/2019	24/07/2019	Please Select...	23/07/2019	G - No patients consented	We identified 6 eligible patients within 70 days but all declined to take part.	Neither
104	155969	18/WM/0372	250761	A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Trial to Evaluate the Efficacy, Safety and Tolerability of ARGX-113 in Patients with Myasthenia Gravis Having Generalized Muscle Weakness	No		2				24/07/2019	04/02/2019	24/07/2019	26/07/2019	Please Select...	24/07/2019	C - Closed by sponsor	Sponsor closed the study early (within 70 days) due to competitive recruitment	Sponsor
105	155970	17/SS/0105	209066	TEMPO-2 - A randomized controlled trial of TNK-tPA versus standard of care for minor ischemic stroke with proven occlusion	No		35				06/08/2019	27/04/2019	09/09/2019	10/09/2019	Please Select...		H - Contracting delays	Contracting delays within Sponsor and UHB	Both
106	155971	18/NW/0359	236897	"NPWT Pre-Registration Study: A Prospective, Multicentre Trial to assess performance, and safety of a single-use negative pressure system. PICO ONBOARD"	Yes	21/08/2019	0	15	15		06/08/2019	21/05/2019	23/07/2019	06/08/2019	Please Select...				Please Select...
107	155972	19/NE/0019	255005	Can vitamin D supplementation in people with Crohn's Disease improve symptoms as an adjunct therapy? D-CODE Feasibility Study.	Yes	03/10/2019			56		08/08/2019	12/03/2019			Please Select...	05/08/2019			Please Select...
108	155973	18/NI/0240	255026	An Observational, Prospective Multicentre Clinical Study to assess the safety and clinical performance of a New Single-use Negative Pressure wound therapy system (PICO 7Y) for the simultanteous management of bilateral closed incisions oncoplastic Breast Surgery Patients	No		0				09/08/2019	24/01/2019	11/07/2019	09/08/2019	Please Select...		E - Staff availability issues	Staff Availability at site	NHS Provider
109	155974	19/LO/1222	251855	A Phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of topically-applied AG013 for the attenuation of oral mucositis in subjects with cancers of the head and neck receiving concomitant chemoradiation therapy	No		0			26/03/2019	14/08/2019	30/01/2019	30/07/2019	14/08/2019	Please Select...	14/08/2019	C - Closed by sponsor	The sponsor closed the study in all uk sites due to unavailability of the drug.	Sponsor
110	155975	19/WA/0092	249143	Developing and Evaluating the Digitally Enhanced Liberation from VEntilation (DELVE)	Yes	02/09/2019			18		15/08/2019	30/05/2019			Please Select...	15/08/2019			Please Select...
111	155976	19/EM/0191	254954	An international multicentre randomised controlled trial to assess the effect of Appendectomy on the Clinical Course of UlceRativE colitis; UK Arm	Yes	20/09/2019	11	21	32		19/08/2019	01/08/2019	23/08/2019	30/08/2019	Please Select...	19/08/2019			Please Select...
112	155977	18/SC/0497	251148	A phase I/IIa, multicentre, open label study designed to evaluate the safety and tolerability of AGI-134 as monotherapy and in combination with pembrolizumab, in unresectable metastatic solid tumours	Yes	12/09/2019			23		20/08/2019	28/01/2019	10/06/2019		Please Select...	19/08/2109			Please Select...

113	155978	18/SC/0666	248460	ORiF Trial: A multicentre randomised controlled trial assessing the mortality, quality of life, and cost effectiveness of operative rib fixation plus supportive management versus supportive management alone for patients with multiple rib fractures requiring ventilator support.	Yes	19/09/2019			29		21/08/2019	28/01/2019	19/08/2019		Please Select...	19/08/2019			Please Select...
114	155979	18/LO/1435	247443	An Open-Label, Multi-Centre Phase I/IIa Study Evaluating the Safety and Clinical Activity of Neoantigen Reactive T cells in Patients with Advanced Non-Small Cell Lung Cancer (CHiRON)	Yes	19/09/2019	0	28	28		22/08/2019	15/02/2019	14/08/2019	22/08/2019	Please Select...	22/08/2019			Please Select...
115	155980	18/WM/0006	225197	An Adaptive, Sequential Evaluation of Powered and Manual Circular Staplers	Yes	16/09/2019			25		22/08/2019	24/04/2019	19/08/2019		Please Select...	22/08/2019			Please Select...
116	155981	19/LO/0109	257158	AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF INTRATHECALLY ADMINISTERED RO7234292 (RG6042) IN PATIENTS WITH HUNTINGTON'S DISEASE	Yes	10/09/2019	1	12	13		28/08/2019	07/03/2019	19/08/2019	29/08/2019	Please Select...	28/08/2019			Please Select...
117	155982	19/LO/0040	253233	Phase 4 Placebo Controlled Study of the Impact of Apremilast on Quality of Life, Efficacy and Safety in Subjects with Manifestations of Plaque Psoriasis and Impaired Quality of Life	Yes	24/09/2019	0	26	26		29/08/2019	19/02/2019	28/08/2019	29/08/2019	Please Select...	21/08/2019			Please Select...
118	155983	17/WM/0421	224749	Role of Implantable Loop Recorders in Anderson-fabry Disease:railroad? a Fabry400 Substudy	Yes	02/09/2019			3		30/08/2019	05/08/2019			Please Select...				Please Select...
119	155984	18/LO/2136	251414	A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRATHECALLY ADMINISTERED RO7234292 (RG6042) IN PATIENTS WITH MANIFEST HUNTINGTON'S DISEASE	Yes	24/09/2019	0	25	25		30/08/2019	22/02/2019	19/08/2019	30/08/2019	Please Select...	30/08/2019			Please Select...
120	155985	18/LO/0997	216343	Brain Imaging to predict Toxicity in Elderly patients after Radiotherapy	No						03/09/2019	28/06/2018			Please Select...	03/09/2019	E - Staff availability issues	Staff Availability	NHS Provider
121	155994	17/WA/0192	227541	Targeted therapeutic mild hypercapnia after resuscitated cardiac arrest: A phase III multi-centre randomised controlled trial	Yes	21/11/2019			78		04/09/2019	13/06/2018			Please Select...	04/09/2019	H - Contracting delays	Contracting delays within NHS Provider	NHS Provider
122	155995	18/EE/0392	248771	Phase II trial of atezolizumab (anti-PD-L1) in the treatment of stage IIb-IV mycosis fungoides/sezary syndrome patients relapsed/refractory after a previous systemic treatment (PARCT)	No		5				04/09/2019	20/04/2019	09/09/2019	09/09/2019	Please Select...	03/09/2019	C - Closed by sponsor	Closed by Sponsor for safety reasons	Sponsor
123	155996	18/NE/0238	250949	A Phase 1 Study of VX-814	No		0				04/09/2019	27/06/2019	26/08/2019	04/09/2019	Please Select...	04/09/2019	D - Sponsor Delays	Sponsor delay in providing lab kits and Laboratory manual	Sponsor
124	155997	18/SC/0395	245499	A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord?, Ex Vivo Expanded, Umbilical Cord Blood-derived, Stem and Progenitor Cells, versus Unmanipulated Umbilical Cord Blood for Patients with Hematological Malignancies	No		0			18/06/2018	13/09/2019	07/01/2019	01/09/2019	13/09/2019	Please Select...	13/09/2019	F - No patients seen	The target for this study is just 1 and we have been unable to find suitable participants who fit the criteria who require a cord transplant	Neither
125	155998	19/WM/0115	254206	An Open-Label, Multicenter, Phase 1 Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Intravenous Doses of Inhibrx rhAAT-Fc (INBRX-101) in Adults with Alpha-1 Antitrypsin Deficiency (AATD)	No		1				17/09/2019	05/06/2019	13/09/2019	18/09/2019	Please Select...	17/09/2019	D - Sponsor Delays	Delayed Sponsor Green Light: It is standard procedure at UHB that the nurses in the WTCRF prepare the IMP. We have had to provide evidence to support this practice which is currently being reviewed by the sponsor. We are also awaiting study-specific training for bronchoscopy from the sponsor.	Sponsor
126	155999	19/YH/0079	259791	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy	No		1			03/10/2018	23/09/2019	09/05/2019	09/09/2019	24/09/2019	Please Select...	23/09/2019	F - No patients seen	Participants sought but no eligible participants identified	Neither
127	156005	18/WM/0361	254302	A Phase I/II Open-Label, Three-Part, Dose-Finding and Separate Cohort Expansion Trial to Assess the Safety, Tolerability and Preliminary Efficacy of Repeated Doses of CLEVER-1 Antibody FP-1305, in Subjects with Advanced Solid Tumours	Yes	10/10/2019	0	16	16	31/08/2018	24/09/2019	18/12/2018	20/09/2019	24/09/2019	Please Select...	24/09/2019			Please Select...
128	156006	19/YH/0015	255446	Beta-blockers Or Placebo for (BOPPP Trial). A blinded, UK multi-centre, clinical effectiveness and cost-effectiveness randomised controlled trial.	Yes	28/11/2019			65	27/02/2019	24/09/2019	24/04/2019			Please Select...	23/09/2019			Please Select...
129	156007	18/LO/1290	249002	A Randomized, Placebo-Controlled, Phase 2 Study of HB-101, a Bivalent Cytomegalovirus (CMV) Vaccine, in CMV-Seronegative Recipient (R-) Patients Awaiting Kidney Transplantation from Living CMV-Seropositive Donors (D+)	No		1				01/10/2019	06/11/2018	27/09/2019	02/10/2019	Please Select...	01/10/2019	G - No patients consented	There are approx just 6 live donor transplants each month, we identified 2 patients that fit the criteria but both declined to participate.	Neither
130	156008	19/SW/0005	256608	Long Term Extension Trial of setmelanotide (RM-493) for patients who have completed a trial of Setmelanotide for the treatment of obesity associated with genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathway	Yes	01/11/2019	0	29	29		03/10/2019	29/03/2019	25/09/2019	03/10/2019	Please Select...	01/11/2019			Please Select...
131	156009	19/EM/0021	258824	A PHASE 3 DOUBLE-BLIND RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF INTRAVENOUS ATB200 CO-ADMINISTERED WITH ORAL AT2221 IN ADULT SUBJECTS WITH LATE-ONSET POMPE DISEASE COMPARED WITH ALGLUCOSIDASE ALFA	Yes	24/10/2019	0	15	15		09/10/2019	25/03/2019	07/10/2019	09/10/2019	Please Select...	09/10/2019			Please Select...
132	156010	17/WS/0210	231280	A placebo controlled rAndomised trial of intravenous Lidocaine in acceLErating Gastrointestinal Recovery after cOlorectal surgery	No						15/10/2019	27/04/2019			Please Select...	15/10/2019	D - Sponsor Delays	Sponsor delays due to protocol amendments	Sponsor
133	156011	18/SC/0242	238151	A phase III randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients.	Yes	19/12/2019			59		21/10/2019	24/08/2019			Please Select...	19/10/2019			Please Select...
134	156012	18/SC/0528	247865	A Phase II, single arm, multicenter open label trial to determine the efficacy and safety of tisagenlecleucel (CTL019) in adult patients with refractory or relapsed follicular lymphoma	No		0			30/08/2018	25/10/2019	07/03/2019	15/10/2019	25/10/2019	Please Select...	25/10/2019			Please Select...
135	156013	19/WM/0217	265937	Prospective, multi-center, single-arm, open-label long-term study assessing the safety, tolerability, and effectiveness of macitentan in Fontan-palliated adult and adolescent subjects.	Yes	21/11/2019	0	27	27		25/10/2019	30/09/2019	16/10/2019	25/10/2019	Please Select...	25/10/2019			Please Select...
136	156014	19/EM/0105	262054	Double-blind, randomised, placebo-controlled, phase IIb trial on the efficacy and safety of norursodeoxycholic acid tablets in patients with non-alcoholic steatohepatitis (NASH)	No		1				19/11/2019	03/06/2019	07/11/2019	20/11/2019	Please Select...	18/11/2019			Please Select...
137	156015	19/NS/0125	262030	A prospective intra-patient single-blinded randomised trial to examine the mechanistic basis of fractional ablative carbon dioxide laser therapy in treating adult burns and/or trauma patients with hypertrophic scarring	No						19/11/2019	06/09/2019			Please Select...	18/11/2019			Please Select...
138	156016	19/WM/0131	252987	An Open-label Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients with Generalized Myasthenia Gravis	No		0				21/11/2019	17/07/2019	12/11/2019	21/11/2019	Please Select...	21/11/2019			Please Select...
139	156017	18/WA/0420	246637	Spironolactone for Adult Female Acne: A pragmatic multicentre double-blind randomised superiority trial to investigate the clinical and cost-effectiveness of spironolactone for moderate or severe persistent acne in women	No					05/03/2019	22/11/2019	04/02/2019			Please Select...				Please Select...
140	156018	19/NW/0490	269017	Efficacy and Safety of Concizumab prophylaxis in patients with haemophilia A or B with inhibitors	No		-3				25/11/2019	30/09/2019	14/11/2019	22/11/2019	Please Select...	25/11/2019			Please Select...
141	156019	18/NE/0210	223922	Defining best Management in Adult Chronic RhinOsinusitis	Yes	20/12/2019			24	22/05/2019	26/11/2019	20/07/2019			Please Select...	26/11/2019			Please Select...
142	156020	18/EE/0241	249199	Open Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegunigalsidase Alfa (PRX-102) in Patients With Fabry Disease	No		0				29/11/2019	26/09/2018	28/11/2019	29/11/2019	Please Select...	29/11/2019			Please Select...
143	156021	19/EM/0099	257917	A phase II multicenter, single arm study of oral BGJ398 in adult patients with advanced or metastatic cholangiocarcinoma with FGFR2 gene fusions or other FGFR genetic alterations who failed or are intolerant to platinum-based chemotherapy	No						06/12/2019	01/07/2019			Please Select...	06/12/2019			Please Select...

144	156022	16/NE/0159	205953	A PHASE 1B/2A MULTICENTER, OPEN-LABEL, DOSEESCALATION STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE, ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF CC-220 MONOTHERAPY AND IN COMBINATION WITH OTHER TREATMENTS IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA	No		0				06/12/2019	13/10/2016	20/11/2019	06/12/2019	Please Select...	06/12/2019			Please Select...
145	156023	19/SC/0352	255747	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis	No		0				18/12/2019	02/08/2019	16/12/2019	18/12/2019	Please Select...	18/12/2019			Please Select...
146	156024	17/NW/0394	225510	An open-label, multi-centre, randomised, two-period, crossover study to assess the efficacy, safety and utility of 16 week day and night automated closed-loop glucose control combined with pump suspend feature under free living conditions compared to sensor augmented insulin pump therapy in older adults with type 1 diabetes	No						20/12/2019	08/08/2019			Please Select...	20/12/2019			Please Select...